Failure of 17-hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double-blind, randomized clinical trial.

Abstract

OBJECTIVE To test whether 17 alpha-hydroxyprogesterone caproate (17P) will reduce neonatal morbidity by increasing gestational age at delivery in triplet pregnancies. STUDY DESIGN Double-blind, randomized clinical trial. Mothers carrying trichorionic-triamniotic triplets were randomly assigned (in a 2:1 ratio) to weekly injections of 250 mg of 17P or… (More)
DOI: 10.1016/j.ajog.2010.06.016

Topics

Cite this paper

@article{Combs2010FailureO1, title={Failure of 17-hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double-blind, randomized clinical trial.}, author={C. Andrew Combs and Thomas J. Garite and Kimberly Maurel and Anita Das and Manuel Porto}, journal={American journal of obstetrics and gynecology}, year={2010}, volume={203 3}, pages={248.e1-9} }